MTSL Issue 833

MTSL Issue 833 (dated 8/11/16) of Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis & updates from these companies: #ACAD #ANTH #BMRN #FPRX #INCY #XON #IONS #MDCO #NKTR #NVAX #PCRX #SGMO #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on

MTSL Issue 829

MTSL Issue 829 (dated 6/09/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #ALKS #FPRX #INCY #IONS #XON #NVAX #MDCO #SGMO #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on

MTSL Issue 826

MTSL Issue 826 (dated 4/28/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #ALKS #BMRN #FPRX #INCY #IONS #NKTR #XON #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on

A Brief Look At Shorts

A Brief Look At Shorts (ACAD, ANTH, BMRN, INCY, IONS, MDCO, NVAX, NKTR, PCRX, ZIOP (for subscribers only).

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on

MTSL Issue 831

MTSL Issue 831 (dated 7/14/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #ANTH #IONS #MDCO #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on

MTSL Issue 828

MTSL Issue 828 (dated 5/26/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on

MTSL Issue 825

MTSL Issue 825 (dated 4/14/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #BMRN #IONS #XON #MDCO

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on

MTSL Issue 822

MTSL Issue 822 (dated 3/3/16) of the Medical Technology #Stock Letter from Bioinvest includes the #Biotech Sector Analysis as well as updates from the following companies: #ACAD #ALKS #BMRN #XON #IONS #NKTR #NVAX #PCRX #SGMO #XON #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on

MTSL Issue 830

MTSL Issue 830 (dated 6/30/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #ANTH #BMRN #FPRX #INCY #IONS #MDCO #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on

MTSL Issue 827

MTSL Issue 827 (dated 5/12/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #ACAD #ANTH #FPRX #INCY #IONS #XON #MDCO #NKTR #NVAX #PCRX #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on

Ionis Update (3-23-16)

IONS Huge Winner as GILD Ruled to Infringe on IONS/Merck HCV Patent –Yesterday, a California District Court jury determined GILD’s blockbuster hepatitis C drugs Sovaldi and Harvoni infringe on two Merck/IONS patents. Read more…

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on
biotech 20

INCY & ISIS – THE NEXT PHASE

CHASING INCY – INCY Poised to Emerge as Oncology Powerhouse, Raising BUY LIMIT – The biggest driver of INCY’s value over the last year, and in our view, going forward has been the emergence of their oncology pipeline.

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on